3:34 PM
 | 
May 14, 2019
 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data
Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in the Phase III LIBERTY 1 trial to treat uterine fibroids (73.4% vs. 18.9%, p<0.0001). Relugolix missed the secondary endpoint of reducing uterine fibroid volume vs. placebo, but met six other secondary endpoints. While the once-daily oral GnRH receptor antagonist offers a convenience advantage over oral GnRH receptor antagonist Orilissa elagolix, which is given twice daily, relugolix's...

Read the full 429 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >